Albumin for bacterial infections other than spontaneous bacterial peritonitis in cirrhosis. A randomized, controlled study.
OBJECTIVE
Treatment with albumin in patients with cirrhosis and spontaneous bacterial peritonitis (SBP) prevents renal failure and improves survival. Whether albumin has similar beneficial effects in patients with infections other than SBP is unknown.


METHODS
One hundred and ten patients with cirrhosis hospitalized for infections other than SBP were randomly assigned to receive antibiotics plus albumin (1.5 g/kgbw at diagnosis and 1 g/kgbw at day 3) (albumin group; n=56) or antibiotics alone (control group; n=54). The primary end point was survival at 3 months. Secondary end points were effects on renal and circulatory function.


RESULTS
The renal function, as evaluated by differences in changes in serum creatinine and estimated glomerular filtration rate between the two groups, improved in patients treated with albumin. The circulatory function improved significantly in patients treated with albumin, but not in those from the control group. There was a trend for a lower frequency of type 1 hepatorenal syndrome in the albumin group compared to the control group (1 vs. 4 patients, respectively; p=n.s.). Probability of survival at 3 months was not significantly different among the two groups. However, when adjusted for factors with independent prognostic value, treatment with albumin was an independent predictive factor of survival.


CONCLUSIONS
As compared with standard antibiotic therapy alone, treatment with albumin together with antibiotics has beneficial effects on the renal and circulatory function and shows a potential survival benefit. Further studies with large sample sizes should be performed to confirm these findings.
Liver Unit, Hospital Clínic, University of Barcelona, Barcelona, Catalunya, Spain.
Mónica
M
Guevara
Carlos
C
Terra
André
A
Nazar
Elsa
E
Solà
Javier
J
Fernández
Marco
M
Pavesi
Vicente
V
Arroyo
Pere
P
Ginès
D000328:Adult; D000368:Aged; D000418:Albumins / Q000494:pharmacology / Q000627:therapeutic use*; D000450:Aldosterone / Q000097:blood; D000900:Anti-Bacterial Agents / Q000494:pharmacology / Q000627:therapeutic use; D009320:Atrial Natriuretic Factor / Q000097:blood; D001424:Bacterial Infections / Q000150:complications / Q000188:drug therapy*; D003404:Creatinine / Q000097:blood; D004359:Drug Therapy, Combination; D005260:Female; D005919:Glomerular Filtration Rate / Q000187:drug effects*; D006439:Hemodynamics / Q000187:drug effects*; D006801:Humans; D053208:Kaplan-Meier Estimate; D007677:Kidney Function Tests; D008103:Liver Cirrhosis / Q000150:complications*; D008297:Male; D008875:Middle Aged; D009638:Norepinephrine / Q000097:blood; D016016:Proportional Hazards Models; D051437:Renal Insufficiency / Q000188:drug therapy; D012083:Renin / Q000097:blood; D015996:Survival Rate
D000418:Albumins; D000900:Anti-Bacterial Agents; D000450:Aldosterone; D009320:Atrial Natriuretic Factor; D003404:Creatinine; D012083:Renin; D009638:Norepinephrine